Dr Alan Roth

Dr. Alan D. Roth, CEO of Oxford Drug Design, has an expansive career, comprising basic research, investment management/capital markets, strategic consultancy and emerging company operations. Starting his career as a chemist at Merck & Co., Inc. in New Lead Discovery, after his academic work he joined McKinsey serving leading companies in a variety of industries. He subsequently became Director at Commerzbank Asset Management, in charge of global equity bio-investments, as well as overall industrial investment research. He co-founded, took public in the US and was first CEO and CFO of Chiral Quest, Inc., a life sciences company in the area of chiral pharmaceuticals. At the University of Oxford, he was awarded the Royal Society Entrepreneur in Residence and is a Visiting Lecturer in the area of science entrepreneurship. Alan earned his BA (Hons) from Cornell University, PhD from Columbia University, and Postdoctoral Fellowship from the University of Oxford in medicinal chemistry.